This study is looking to see if giving ranolazine to subjects on stable pulmonary hypertension therapies but with right ventricular dysfunction (RVEF \<45%) will improve their health by improving right ventricular (RV) function.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
22
Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
Placebo by mouth twice per day for a total of 26 weeks
University of Maryland
Baltimore, Maryland, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Absolute Change From Baseline Right Ventricular Ejection Fraction (the Unit is Percentage)
Change in right ventricle ejection fraction as assessed by MRI
Time frame: 26 weeks
Percent Change in 6min-walk-test Distance
6-minute walk test
Time frame: 6 months
Change in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)
NT-proBNP measured at 6-months compared to baseline
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.